Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

NCT02250170 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02250170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02250170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
Lead sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2014
Completion date
March 8, 2019
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor